Flipping Book - Hema

Background Image

Previous Page

Next Page

Page Background

BCL-2 Inhibition

Bcl-2 highly expressed in FL

GDC-0199 oral active Bcl-2 inhibitor

Phase I dose escalation

200-900 mg cohorts

N=44 with NHL

FL =11 (26%)

Nausea (34%), diarrhoea (25%), fatigue (21%)

Tumour lysis in 1 patient each with DLBCL and

MCL

3/11 responses in FL

GDC-0199